Aligos Therapeutics (ALGS) Other Non-Current Liabilities (2019 - 2024)

Aligos Therapeutics has reported Other Non-Current Liabilities for 6 years, with the latest figure at $72.4 million in Q4 2024.

• For the quarter ending Q4 2024, Other Non-Current Liabilities rose 162.24% year-over-year to $72.4 million; the trailing twelve-month figure through Dec 2024 stood at $72.4 million (up 162.24% YoY), and the FY2024 full-year result was $72.4 million, up 162.24% from the prior year.
• Other Non-Current Liabilities for Q4 2024 stood at $72.4 million, up from $11.6 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $72.4 million in Q4 2024, with the low at $133000.0 in Q4 2021.
• Historically, Other Non-Current Liabilities has averaged $12.8 million across 5 years, with a median of $267000.0 in 2021.
• Annual changes were most pronounced in 2021 — Other Non-Current Liabilities sank 56.94% — and 2024, when it jumped 162.24%.
• Aligos Therapeutics' Other Non-Current Liabilities stood at $620000.0 in 2020, then tumbled by 78.55% to $133000.0 in 2021, then changed by 0.0% to $133000.0 in 2022, then jumped by 20648.87% to $27.6 million in 2023, then surged by 162.24% to $72.4 million in 2024.
• The last three Other Non-Current Liabilities figures came in at $72.4 million (Q4 2024), $11.6 million (Q3 2024), and $11.5 million (Q2 2024), per Business Quant data.